Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials
Jorge E Cortes, Hervé Dombret, Akil Merchant, Tetsuzo Tauchi, Christine G DiRienzo, Barbara Sleight, Xiaoxi Zhang, Eric P Leip, Naveed Shaik, Timothy Bell, Geoffrey Chan, Mikkael A Sekeres, Jorge E Cortes, Hervé Dombret, Akil Merchant, Tetsuzo Tauchi, Christine G DiRienzo, Barbara Sleight, Xiaoxi Zhang, Eric P Leip, Naveed Shaik, Timothy Bell, Geoffrey Chan, Mikkael A Sekeres
Abstract
Glasdegib, an oral Hedgehog pathway inhibitor, has been associated with significantly improved survival when combined with low-dose cytarabine in patients with untreated acute myeloid leukemia (AML) who were unsuitable for intensive chemotherapy, when compared with low-dose cytarabine alone. BRIGHT AML 1019 (NCT03416179) comprises two independently powered Phase III, randomized (1:1), double-blind global trials evaluating oral glasdegib 100 mg once daily or placebo plus one of two standard chemotherapy regimens in adults with untreated AML. The intensive trial combines glasdegib/placebo with cytarabine and daunorubicin (7 + 3), while the nonintensive trial combines glasdegib/placebo with azacitidine. The primary end point of both studies is overall survival. Secondary end points include response, time to and duration of response, event-free survival, safety, patient-reported outcomes and pharmacokinetics. Trial registration number: ClinicalTrials.gov identifier: NCT03416179.
Keywords: Hedgehog signaling pathway; acute myeloid leukemia; glasdegib; intensive chemotherapy; myelodysplastic syndrome; nonintensive chemotherapy; smoothened inhibitor.
Source: PubMed